Cargando…
Mepolizumab does not alter the blood basophil count in severe asthma
Autores principales: | Wright, Adam Kelvin Alec, Diver, Sarah, McCarthy, Jamie, Marvin, Andrew, Soares, Marcia, Thornton, Tracy, Bourne, Michelle, Craner, Michelle, Evans, Helen, Edwards, Sarah, Glover, Sarah, Carr, Liesl, Parker, Sarah, Siddiqui, Salman, Cousins, David, Brightling, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973167/ https://www.ncbi.nlm.nih.gov/pubmed/31106444 http://dx.doi.org/10.1111/all.13879 |
Ejemplares similares
-
Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022) -
Mepolizumab and COPD in Real Life
por: Revuelta-Salgado, Fernando, et al.
Publicado: (2021) -
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021) -
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder
por: Baek, Ji Hyun, et al.
Publicado: (2016) -
Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)